Investment Summary

HBM Partners AG Invests In Farmalisto

On January 15, 2021, private equity firm HBM Partners AG invested in life science company Farmalisto

Investment Highlights
  • This is HBM Partners AG’s 46th transaction in the Life Science sector.
  • This is HBM Partners AG’s 1st transaction in Colombia.

Investment Summary
Date 2021-01-15
Target Farmalisto
Sector Life Science
Investor(s) HBM Partners AG
Deal Type Growth Capital

Target

Farmalisto

Bogotá, Colombia
Farmalisto is a technology healthcare platform in Latin America that connects providers and users of the healthcare system to enhance value creation and delivery to end customers. The company has operations in Mexico, Colombia, and Chile. Farmalisto is expanding its services to become a partner of choice for pharmaceutical companies in logistics, marketing and disease management. Farmalisto was founded in 2013 and is based in Bogotá, Colombia.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

HBM Partners AG

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2001
PE ASSETS 3.0B USD
Size Mega
Type Sector Focused
DESCRIPTION

HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.

DEAL STATS #
Overall 53 of 66
Sector (Life Science) 46 of 57
Type (Growth Capital) 5 of 7
Country (Colombia) 1 of 1
Year (2021) 5 of 15
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-01-13 IO Biotech

Copenhagen, Denmark

IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. IO Biotech's pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. IO Biotech was founded in 2014 and is based in Copenhagen, Denmark.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-02-01 Viela Bio

Gaithersburg, Maryland, United States

Viela Bio is dedicated to the development and commercialization of novel, life-changing medicines for patients with a wide range of autoimmune and severe inflammatory diseases. Viela Bio was founded in 2018 and is based in Gaithersburg, United States.

Sell $3.1B
Mergr

Product

Company

Legal